Our goal is to improve the health and quality of life for people living with rare diagnoses. Our research and development takes into account patient needs in order to deliver innovative therapies and contribute with long-term results. Initially, our focus is on neuromuscular diseases, specifically Duchenne muscular dystrophy (DMD).
This image is AI-generated
ITALFARMACO Group (ITF) was founded more than 85 years ago, driven by the passion to develop medicines within a wide range of disease areas. It is one of the leading global Italian companies active within both the pharmaceutical and chemical industry. The Nordic organization, which is headquartered in Stockholm but works actively in all the Nordic countries, was established in 2024 and specializes in rare disease. In collaboration with the expertise within the ITALFARMACO Group, we look forward to contributing to valuable developments and new treatment options. Our local representative, CampusPharma AB, is responsible for our medicines in other therapeutic areas that are marketed in the Nordics, for example products in the field of women’s health and neurology.
Duchenne muscular dystrophy (DMD) is a rare and difficult diagnosis that affects between 3 and 5 per 100,000 people in the Nordics. Our work is focused on meeting the need for innovative therapies, whilst in parallel, increasing the knowledge and awareness surrounding neuromuscular diseases, specifically, Duchenne muscular dystrophy.
DK-ITFRD-24-00003 October 2024
Italfarmaco Nordics
The Park Forskaren
Hagaplan 4
113 68, Stockholm, SWEDEN
Copyright © Italfarmaco Nordics. All rights reserved.
EN 
SE